EPS for ABIOMED, Inc. (ABMD) Expected At $0.64

April 21, 2018 - By Larry Anderson

ABIOMED, Inc. (NASDAQ:ABMD) LogoInvestors sentiment decreased to 1.18 in Q4 2017. Its down 0.12, from 1.3 in 2017Q3. It fall, as 19 investors sold ABIOMED, Inc. shares while 110 reduced holdings. 55 funds opened positions while 97 raised stakes. 36.44 million shares or 5.39% less from 38.51 million shares in 2017Q3 were reported.
Huntington Fincl Bank has invested 0% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Regions Fincl owns 0% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 70 shares. Balyasny Asset Management Ltd Limited Liability Company owns 23,812 shares. Great West Life Assurance Can holds 0.01% or 29,976 shares in its portfolio. Pillar Pacific Cap Mngmt Limited Liability Company accumulated 2,200 shares or 0.05% of the stock. Mirae Asset Glob Invs Limited reported 10,450 shares. Grp Inc Inc One Trading L P stated it has 0% in ABIOMED, Inc. (NASDAQ:ABMD). Gideon invested in 1,222 shares. Texan Cap Mngmt stated it has 1.32% in ABIOMED, Inc. (NASDAQ:ABMD). Hermes Ltd has invested 0.38% in ABIOMED, Inc. (NASDAQ:ABMD). Sg Americas Ltd owns 24,078 shares or 0.04% of their US portfolio. 379,886 were accumulated by Blair William Company Il. Illinois-based Oakbrook Invs Ltd Liability Co has invested 0.04% in ABIOMED, Inc. (NASDAQ:ABMD). Tiaa Cref Inv Management Ltd Company holds 165,688 shares or 0.02% of its portfolio. 1.12 million were reported by State Street Corp.

Since February 20, 2018, it had 0 insider purchases, and 1 sale for $5.41 million activity.

Analysts expect ABIOMED, Inc. (NASDAQ:ABMD) to report $0.64 EPS on May, 3 before the open.They anticipate $0.31 EPS change or 93.94 % from last quarter’s $0.33 EPS. ABMD’s profit would be $28.34 million giving it 119.50 P/E if the $0.64 EPS is correct. After having $0.70 EPS previously, ABIOMED, Inc.’s analysts see -8.57 % EPS growth. The stock decreased 0.17% or $0.53 during the last trading session, reaching $305.92. About 258,641 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 128.67% since April 21, 2017 and is uptrending. It has outperformed by 117.12% the S&P500.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Among 8 analysts covering Abiomed (NASDAQ:ABMD), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Abiomed had 12 analyst reports since November 2, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Friday, February 2 by Guggenheim. The firm has “Buy” rating given on Monday, April 9 by Stephens. The firm has “Buy” rating by SunTrust given on Friday, February 16. The firm has “Buy” rating given on Thursday, January 4 by Piper Jaffray. The rating was maintained by Morgan Stanley with “Equal-Weight” on Friday, February 2. Jefferies maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Thursday, December 21. Jefferies has “Buy” rating and $220.0 target. The rating was maintained by Stephens with “Buy” on Friday, February 2. Jefferies maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Thursday, February 1. Jefferies has “Buy” rating and $300.0 target. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Thursday, November 2 by Jefferies. The firm has “Buy” rating given on Thursday, February 1 by Piper Jaffray.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company has market cap of $13.55 billion. It also provides continuum of care to heart failure patients. It has a 153.5 P/E ratio. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: